Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Rubin

Showing results (431-440 of 785) with videos related to

Pageof 79
Sort By:
Plos One|August 25, 2017
Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel diseaseDejan Micic, John N Gaetano, Jonah N Rubin, et al.
Oncotarget|May 15, 2018
Increased mucosal expression of miR-215 precedes the development of neoplasia in patients with long-standing ulcerative colitisJoel Pekow, Katherine Meckel, Urszula Dougherty, et al.
Clinical and Experimental Gastroenterology|July 30, 2019
Patient and physician preferences for ulcerative colitis treatments in the United StatesMarco Boeri, Kelley Myers, Claire Ervin, et al.
Gut|August 28, 2020
Emerging treatment options for extraintestinal manifestations in IBDThomas Greuter, Florian Rieder, Torsten Kucharzik, et al.
Annals of Surgery|November 1, 1984
Parathyroid surgery in patients with renal failureF L Delmonico, C A Wang, N T Rubin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 19, 2016
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor AntagonistsBrian G Feagan, David T Rubin, Silvio Danese, et al.
Digestive Diseases and Sciences|September 5, 2009
Do colorectal cancer patients understand that their family is at risk?David T Rubin, Rishi K Gandhi, Jeremy T Hetzel, et al.
Journal of Managed Care & Specialty Pharmacy|May 14, 2019
Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug SpendingDiana Brixner, David T Rubin, Philip Mease, et al.
BMC Gastroenterology|September 17, 2024
Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARYNoa Krugliak Cleveland, Sabyasachi Ghosh, Benjamin Chastek, et al.
Digestive Diseases and Sciences|June 4, 2026
Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel DiseaseNavneet Natt, David Choi, Asher Shafrir, et al.
Pageof 79

Showing results (431-440 of 785) with videos related to

Sort By:
Pageof 79
Plos One|August 25, 2017
Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel diseaseDejan Micic, John N Gaetano, Jonah N Rubin, et al.
Oncotarget|May 15, 2018
Increased mucosal expression of miR-215 precedes the development of neoplasia in patients with long-standing ulcerative colitisJoel Pekow, Katherine Meckel, Urszula Dougherty, et al.
Clinical and Experimental Gastroenterology|July 30, 2019
Patient and physician preferences for ulcerative colitis treatments in the United StatesMarco Boeri, Kelley Myers, Claire Ervin, et al.
Gut|August 28, 2020
Emerging treatment options for extraintestinal manifestations in IBDThomas Greuter, Florian Rieder, Torsten Kucharzik, et al.
Annals of Surgery|November 1, 1984
Parathyroid surgery in patients with renal failureF L Delmonico, C A Wang, N T Rubin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 19, 2016
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor AntagonistsBrian G Feagan, David T Rubin, Silvio Danese, et al.
Digestive Diseases and Sciences|September 5, 2009
Do colorectal cancer patients understand that their family is at risk?David T Rubin, Rishi K Gandhi, Jeremy T Hetzel, et al.
Journal of Managed Care & Specialty Pharmacy|May 14, 2019
Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug SpendingDiana Brixner, David T Rubin, Philip Mease, et al.
BMC Gastroenterology|September 17, 2024
Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARYNoa Krugliak Cleveland, Sabyasachi Ghosh, Benjamin Chastek, et al.
Digestive Diseases and Sciences|June 4, 2026
Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel DiseaseNavneet Natt, David Choi, Asher Shafrir, et al.
Pageof 79